Intellia Therapeutics Announces FDA Acceptance Of Biologics License Application With Priority Review For Lonvoguran Ziclumeran (Lonvo-Z) For Hereditary Angioedema (Hae)

Sept. 8 (Reuters) - Intellia Therapeutics, Inc. (NTLA.O) said the FDA has accepted its biologics license application for lonvoguran ziclumeran (Lonvo-Z) for hereditary angioedema (HAE) and granted priority review.

• The company said the FDA assigned a PDUFA date of March 10, 2027.
• Intellia said the FDA is not planning to hold an advisory committee meeting for the application.